Guideline document

Your browser can't display PDFs inline. Open the guideline in a new tab.

This guideline is provided for in-page reading only. Please contact the publishing organization for downloadable copies.

0 Views
0 Likes
0 Shares
0 Comments

StayCurrentMD

View profile →

Clinical Guideline

Hematopoietic Cell Transplantation PDQ®

Topic overview

Evidence-based clinical reference from the National Cancer Institute for healthcare professionals managing pediatric hematopoietic cell transplantation. Covers indications, protocols, and outcomes for stem cell and bone marrow transplantation in children with hematologic malignancies and other conditions requiring cellular therapy.

Key Takeaways

  • Hematopoietic cell transplantation (HCT) is a curative treatment option for various pediatric malignancies and non-malignant hematologic disorders.
  • Transplant types include autologous (patient's own cells) and allogeneic (donor cells), each with distinct indications and risk profiles.
  • Graft-versus-host disease (GVHD) remains a major complication of allogeneic HCT, requiring careful immunosuppression management.
  • Conditioning regimens (chemotherapy ± radiation) prepare the patient for transplant but carry significant toxicity risks in children.
  • Long-term survivorship care is essential post-HCT due to risks of secondary malignancies, organ dysfunction, and growth/developmental issues.

Keywords

Hematopoietic Cell Transplantation Pediatric Oncology Bone Marrow Transplant Stem Cell Transplantation Childhood Cancer Treatment Hematologic Malignancies

Hashtags

#PediatricTransplant #HCT #ChildhoodCancer #StemCellTherapy

Full guideline text

Full text not available for this guideline
How to cite: GlobalCastMD. Hematopoietic Cell Transplantation PDQ®. GlobalCastMD Medical Library. https://library.globalcastmd.com/guideline/2376

Comments

Loading comments...